Faculty of Medical Sciences, Department of Microbiology and immunology, Center for Molecular Medicine and Stem Cell Research, University of Kragujevac, Serbia, 69 Svetozar Markovic Street, 34000, Kragujevac, Serbia.
Faculty of Medical Sciences, Department of Dentistry, University of Kragujevac, Serbia, 69 Svetozar Markovic Street, 34000, Kragujevac, Serbia.
Stem Cell Rev Rep. 2018 Apr;14(2):153-165. doi: 10.1007/s12015-017-9789-2.
Mesenchymal stem cells (MSCs) are promising resource for the therapy of inflammatory bowel diseases (IBDs) on the grounds of their differentiation capabilities and immuno-modulatory characteristics. Results of clinical studies indicate that local application of MSCs is a secure and beneficial approach for the treatment of perianal fistulas while systemic application of MSCs leads to the attenuation or aggravation of IBDs. Herein, we emphasized molecular mechanisms and approaches that should improve efficacy of MSC-based therapy of IBDs.
间充质干细胞（MSCs）具有分化能力和免疫调节特性，有望成为治疗炎症性肠病（IBDs）的一种资源。临床研究结果表明，MSC 的局部应用是治疗肛周瘘管的一种安全有效的方法，而 MSC 的全身应用则导致 IBDs 的加重或恶化。在此，我们强调了应改善基于 MSC 的 IBD 治疗疗效的分子机制和方法。
Curr Stem Cell Res Ther. 2017
Curr Stem Cell Res Ther. 2015
Mol Ther. 2010-4-13
Biomacromolecules. 2024-10-14
Gastroenterol Hepatol (N Y). 2024-4
Nat Rev Gastroenterol Hepatol. 2022-8
Front Cell Dev Biol. 2022-2-18
Stem Cell Res Ther. 2017-9-29
Expert Rev Gastroenterol Hepatol. 2017-6-26
Lancet Gastroenterol Hepatol. 2017-4-6
Handb Exp Pharmacol. 2017
Zotero 插件